More than three years after medical cannabis has been legalised in the UK, the first Patient Representative Board is about to open.
According to an announcement from the LYPHE Group, the newly created Patient Representative Board will focus on patient concerns and industry issues and will be formed of independent patients from across the UK, the Channel Islands and the Isle of Man, as well as representatives from patient groups and charities.
Since the rescheduling of medical cannabis in November 2018, LYPHE has been leading the way in patient access, with the large majority of patients using its clinical services and dispensary to obtain medication.
LYPHE has created the industry’s first Patient Representative Board to ensure patient voices are heard.
Meetings will be held monthly, and feedback from the sessions will be used to further explore how to improve the patient experience.
It was announced that by working together, LYPHE hopes to bring about changes that will benefit the wider patient community, as well as shape the organisation’s future direction.
Discussing the initiative, LYPHE Group Managing Director Jonathan Nadler, said: “I’m delighted LYPHE is taking the initiative in working closely with patients. We want to build a stronger, more sustainable industry whilst continuing our journey for full patient access.
“The issues that impact our business, and the medical cannabis industry, ultimately impact our patients, which is why improving transparency with patient groups is vital.”
For more information on how to apply visit www.lyphegroup.com.
Applicants or patient groups can register their interest by emailing their details along with reasons why they would like to join the Board via the contact form. Membership will be limited to a total of 12 representatives in addition to the two Chairs.
